×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Articles

Kristie L. Kahl
The replacement of vincristine with Velcade (bortezomib) in the R-CHOP regimen for the treatment of transplantation-ineligible patients with newly diagnosed mantle cell lymphoma improved overall survival in a final analysis of the LYM-3002 trial.
 
Jessica Skarzynski
After seeing encouraging phase 1 results, the phase 2 portion of a clinical trial currently evaluating the efficacy of the BET inhibitor CPI-0610 in patients with myelofibrosis has been enhanced and expanded.
Brielle Urciuoli
For many patients with polycythemia vera, hydroxyurea is a beneficial first-line treatment. But that’s not the case for everyone. One expert discusses which drugs should be used next.
Katie Kosko
The immunotherapy agent Keytruda is showing promise for treating non-muscle invasive bladder cancer, according to a recent study.
Katie Kosko
Understanding the type of MPN can affect how care is carried out and how well it may work.
Kristie L. Kahl
A recent study found that fatigue reported among newly diagnosed patients with multiple myeloma may predict survival outcomes.
Kristie L. Kahl
Preliminary findings showed that Revlimid (lenalidomide) significantly prolonged progression-free survival compared with observation in patients with smoldering multiple myeloma.
Jessica Skarzynski
The anti-PD-1 monoclonal antibody TSR-042 may be safe and effective for the treatment of patients with microsatellite-high (MSI-H) endometrial cancer.
 
Kristie L. Kahl
A blood test may help to identify a subset of patients with mantle cell lymphoma and determine the management of outcomes of these individuals.
 
Jessica Skarzynski and Kristie L. Kahl
After receiving a breast cancer diagnosis “out of the blue” in 1996, Sue Friedman would later come to find out she also has a BRCA2 genetic mutation – a discovery that would lead to the creation of an organization for individuals in a similar situation.
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other